Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer

American Journal of Clinical Pathology

Volumn 141, Issue 3, 2014, Pages 323-333

  Dean, Sarah J R ^a   Perks, Claire M ^b   Holly, Jeff M P ^b   Bhoo Pathy, Nirmala ^c,d   Looi, Lai Meng ^e   Mohammed, Nur Aishah Taib ^e   Mun, Kein Seong ^e   Teo, Soo Hwang ^e,f   Koobotse, Moses O ^a   Yip, Cheng Har ^e   Rhodes, Anthony ^a,e  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d HOSPITAL KUALA LUMPUR   (Malaysia)

^e UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^f CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

Author keywords

IGFBP2; Pten loss

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; KERATIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STAINING; TRIPLE NEGATIVE BREAST CANCER; YOUNG ADULT; AGE; DISEASE COURSE; IGFBP2; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PTEN LOSS; SURVIVAL RATE;

IGFBP2; PTEN LOSS;

ADULT; AGE FACTORS; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; KERATINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84897944076     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPR11DEAYPTUSL     Document Type: Article

References (50)

1. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109:1721-1728.
2. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52:108-118.
3. Tan GH, Taib NA, Choo WY, et al. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. 2009;10:395-398.
4. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116:317-328.
5. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
6. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
7. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
8. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
9. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27-44.
10. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692.
11. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133:403-414.
12. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128:157-170.
13. Panigrahi AR, Pinder SE, Chan SY, et al. The role of PTEN and its signaling pathways, including AKT, in breast cancer: an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004;204:93-100.
14. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253-1260.
15. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2009;126:1121-1131.
16. Perks CM, Vernon EG, Rosendahl AH, et al. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene. 2007;26:5966-5972.
17. Meinbach DS, Lokeshwar BL. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Urol Oncol. 2006;24:294-306.
18. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873-877.
19. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149:461-471, W83-88.
20. Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology. 2006;83:154-60.
21. Busund LT, Richardsen E, Busund R, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 2005;58:361-366.
22. Wang H, Arun BK, Wang H, et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008;14:261-267.
23. Wang M, Liu YE, Ni J, et al. Induction of mammary differentiation by mammary-derived growth inhibitor-related gene that interacts with an uω-3 fatty acid on growth inhibition of breast cancer cells. Cancer Res. 2000;60:6482-6487.
24. Gebauer G, Jager W, Lang N. mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res. 1998;18:1191-1195.
25. McGuire SE, Hilsenbeck SG, Figueroa JA, et al. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994;77:25-32.
26. So AI, Levitt RJ, Eigl B, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 2008;14:6944-6954.
27. Degraff DJ, Aguiar AA, Sikes RA. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res. 2009;1:115-130.
28. Yan XJ, Tian Y, Wang C, et al. The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:639-643.
29. Zhang L, Huang W, Chen J, et al. Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation. Dig Dis Sci. 2007;52:248-253.
30. Shi Z, Henwood MJ, Bannerman P, et al. Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A. Growth Horm IGF Res. 2007;17:113-121.
31. Miyake H, Hara I, Yamanaka K, et al. Introduction of insulinlike growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep. 2005;13:341-345.
32. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factorbinding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007;104:5563-5568.
33. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I, the value of histological grade in breast cancer-experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
34. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37-47.
35. Rhodes A, Sarson J, Assam EE, et al. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010;134:621-632.
36. Hammond ME, Hayes DF, Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6:195.
37. Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology, College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
38. Pallares J, Bussaglia E, Martinez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol. 2005;18:719-727.
39. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324-3330.
40. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 2001;14:672-676.
41. Kiyama S, Morrison K, Zellweger T, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 2003;63:3575-3584.
42. Azar WJ, Azar SH, Higgins S, et al. IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology. 2011;152:3332-3342.
43. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233-242.
44. Scrideli CA, Carlotti CG Jr, Mata JF, et al. Prognostic significance of co-overexpression of the EGFR/IGFBP-2/ HIF-2A genes in astrocytomas. J Neurooncol. 2007;83:233-239.
45. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer: current status and future directions. Ann Oncol. 2009;20:1913-1927.
46. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989-997.
47. Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulinlike growth factor binding protein-2. Biochem Biophys Res Commun. 2005;336:1056-1061.
48. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23:1515-1527.
49. Vazquez F, Ramaswamy S, Nakamura N, et al. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000;20:5010-5018.
50. Torres J, Navarro S, Roglá I, et al. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur J Cancer. 2001;37:114-121.